EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study

Ali Altharawi iD, Mohammed M Alanazi iD, Manal A Alossaimi iD, Ashwag S Alanazi, Safar M Alqahtani iD, Mohammed H Geesi iD, Yassine Riadi iD

Molecules · 20.07.2023 · 28 (14) · 5548

DOI: 10.3390/molecules28145548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 20.07.2023. Verfasst von Ali Altharawi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Prince Sattam Bin Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The discovery of multi-targeted kinase inhibitors emerged as a potential strategy in the therapy of multi-genic diseases, such as cancer, that cannot be effectively treated by modulating a single biological function or pathway. The current work presents an extension of our effort to design and synthesize a series of new quinazolin-4-one derivatives based on their established anti-cancer activities as inhibitors of multiple protein kinases. The cytotoxicity of the new derivatives was evaluated against a normal human cell line (WI-38) and four cancer lines, including HepG2, MCF-7, MDA-231, and HeLa. The most active compound, 5d, showed broad-spectrum anti-cancer activities against all tested cell lines (IC50 = 1.94–7.1 µM) in comparison to doxorubicin (IC50 = 3.18–5.57 µM). Interestingly, compound 5d exhibited lower toxicity in the normal WI-38 cells (IC50 = 40.85 µM) than doxorubicin (IC50 = 6.72 µM), indicating a good safety profile. Additionally, the potential of compound 5d as a multi-targeted kinase inhibitor was examined against different protein kinases, including VEGFR2, EGFR, HER2, and CDK2. In comparison to the corresponding positive controls, compound 5d exhibited comparable activities in nanomolar ranges against HER2, EGFR, and VEGFR2. However, compound 5d was the least active against CDK2 (2.097 ± 0.126 µM) when compared to the positive control roscovitine (0.32 ± 0.019 µM). The apoptotic activity investigation in HepG2 cells demonstrated that compound 5d arrested the cell cycle at the S phase and induced early and late apoptosis. Furthermore, the results demonstrated that the apoptosis pathway was provoked due to an upregulation in the expression of the proapoptotic genes caspase-3, caspase-9, and Bax and the downregulation of the Bcl-2 anti-apoptotic gene. For the in silico docking studies, compound 5d showed relative binding interactions, including hydrogen, hydrophobic, and halogen bindings, with protein kinases that are similar to the reference inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsHumansMolecular StructureStructure-Activity RelationshipMolecular Docking SimulationCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorErbB ReceptorsDoxorubicinApoptosisProtein Kinase Inhibitors

Stichwörter der Autor:innen

apoptosiscytotoxicitymolecular dockingprotein kinasesquinazolin-4(3H)-one

Substanzen

Antineoplastic AgentsErbB ReceptorsDoxorubicinProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11541, Saudi Arabia.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 84428, Saudi Arabia.
  • Department of Chemistry, College of Science and Humanities in Al-Kharj, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.

ORCID-Profile: Ali Altharawi, Mohammed M Alanazi, Manal A Alossaimi, Safar M Alqahtani, Mohammed H Geesi, Yassine Riadi

Förderung

  • Prince Sattam Bin Abdulaziz University

Zitieren

APA

Altharawi, A., Alanazi, M. M., Alossaimi, M. A., Alanazi, A. S., Alqahtani, S. M., Geesi, M. H., & Riadi, Y. (2023). Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study. Molecules, 28(14), 5548. https://doi.org/10.3390/molecules28145548

Vancouver

Altharawi A, Alanazi MM, Alossaimi MA, Alanazi AS, Alqahtani SM, Geesi MH, et al. Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study. Molecules. 2023;28(14):5548. doi:10.3390/molecules28145548

BibTeX
@article{Altharawi2023,
  author = {Altharawi, Ali and Alanazi, Mohammed M and Alossaimi, Manal A and Alanazi, Ashwag S and Alqahtani, Safar M and Geesi, Mohammed H and Riadi, Yassine},
  title = {Novel 2-Sulfanylquinazolin-4(3H)-one Derivatives as Multi-Kinase Inhibitors and Apoptosis Inducers: A Synthesis, Biological Evaluation, and Molecular Docking Study},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {14},
  pages = {5548},
  doi = {10.3390/molecules28145548}
}
Kostenlos starten →